Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experien

Antonio C. Wolff, Amanda L. Blackford, Kala Visvanathan, Hope S. Rugo, Beverly Moy, Lori J. Goldstein, Keith Stockerl-Goldstein, Leigh Neumayer, Terry S. Langbaum, Richard L. Theriault, Melissa E. Hughes, Jane C. Weeks, Judith E. Karp

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Purpose Outcomes for early-stage breast cancer have improved. First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cumulative incidence of myelodysplastic syndrome/acute myelogenous leukemia. Incomplete ascertainment and follow-up may have underestimated subsequent risk of treatment-associated marrow neoplasm (MN). Patients and Methods We examined the MN frequency in 20,063 patients with stage I to III breast cancer treated at US academic centers between 1998 and 2007. Time-to-event analyses were censored at first date of new cancer event, last contact date, or death and considered competing risks. Cumulative incidence, hazard ratios (HRs), and comparisons with Surveillance, Epidemiology, and End Results estimates were obtained. Marrow cytogenetics data were reviewed. Results Fifty patients developed MN (myeloid, n = 42; lymphoid, n = 8) after breast cancer (median follow-up, 5.1 years). Patients who developed MN had similar breast cancer stage distribution, race, and chemotherapy exposure but were older compared with patients who did not develop MN (median age, 59.1 v 53.9 years, respectively; P = .03). Two thirds of patients had complex MN cytogenetics. Risk of MN was significantly increased after surgery plus chemotherapy (HR, 6.8; 95% CI, 1.3 to 36.1) or after all modalities (surgery, chemotherapy, and radiation; HR, 7.6; 95% CI, 1.6 to 35.8), compared with no treatment with chemotherapy. MN rates per 1,000 person-years were 0.16 (surgery), 0.43 (plus radiation), 0.46 (plus chemotherapy), and 0.54 (all three modalities). Cumulative incidence of MN doubled between years 5 and 10 (0.24% to 0.48%); 9% of patients were alive at 10 years. Conclusion In this large early-stage breast cancer cohort,MNrisk after radiation and/or adjuvant chemotherapy was low but higher than previously described. Risk continued to increase beyond 5 years. Individual risk ofMNmust be balanced against the absolute survival benefit of adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)340-348
Number of pages9
JournalJournal of Clinical Oncology
Volume33
Issue number4
DOIs
StatePublished - Feb 1 2015

Fingerprint Dive into the research topics of 'Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experien'. Together they form a unique fingerprint.

  • Cite this

    Wolff, A. C., Blackford, A. L., Visvanathan, K., Rugo, H. S., Moy, B., Goldstein, L. J., Stockerl-Goldstein, K., Neumayer, L., Langbaum, T. S., Theriault, R. L., Hughes, M. E., Weeks, J. C., & Karp, J. E. (2015). Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experien. Journal of Clinical Oncology, 33(4), 340-348. https://doi.org/10.1200/JCO.2013.54.6119